Premium
Molecular Pharmacology and Therapeutic Prospects of Metabotropic Glutamate Receptor Allosteric Modulators
Author(s) -
Ritzén Andreas,
Mathiesen Jesper Mosolff,
Thomsen Christian
Publication year - 2005
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2005.pto_156.x
Subject(s) - metabotropic glutamate receptor , neuroscience , allosteric regulation , metabotropic glutamate receptor 5 , metabotropic glutamate receptor 3 , schizophrenia (object oriented programming) , pharmacology , anxiety , epilepsy , metabotropic receptor , allosteric modulator , glutamate receptor , metabotropic glutamate receptor 2 , class c gpcr , metabotropic glutamate receptor 7 , medicine , biology , receptor , psychiatry
The metabotropic glutamate receptors (mGluR) consist of a family of eight G‐protein‐coupled receptors that differ in their function, distribution and physiological roles within the central nervous system. In recent years substantial efforts have been made towards developing selective agonists and antagonists which have proven useful for elucidating their potential as novel targets for the treatment of psychiatric and neurological diseases. In the present review we will provide an update of the recent developments of functional allosteric modulators of the mGluR family and explore their therapeutic potential for anxiety/depression, schizophrenia, epilepsy/stroke, pain and Alzheimer's, Parkinson's and Huntington's diseases.